Liver Embolization Approaches for Tumor Management

Liver Embolization Approaches for Tumor Management - Retrospective and Prospective Analysis of the Short-, Medium-, and Long-term Clinical Course of Patients Subjected to Embolization Treatment for Primary and Secondary Liver Neoplasms

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05714124

Acronym

LEATUM

Enrollment

580

Registered

2023-02-06

Start date

2021-05-21

Completion date

2031-12-31

Last updated

2024-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiocarcinoma, Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Colon Cancer, Metastatic Gastric Cancer, Metastatic Pancreatic Cancer, Primary Liver Cancer

Keywords

embolization, TAE, TACE, TARE, PVE, HVE

Brief summary

The goal of this evaluate short, medium and long term outcome of the different embolization techniques in patients with primary and secondary hepatic tumors. The main aim is to evaluate progression free survival following embolization in this study population or evaluate residual hepatic volume in cases in which these techniques are used to induce liver regeneration. This study is an observational registry - all patients will follow their normal therapeutic and treatment scheme as per clinical practice, without any additional intervention.

Interventions

PROCEDUREEmbolization

Endovascular treatment for patients with primary and secondary liver tumors

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ≥ 18 yoa * patients with patients with primary or secondary liver disease not amenable for surgery or ablation * patients with primary or secondary liver tumors candidates for major surgery prior to induction of hypertrophy * able and willing to sign informed consent

Exclusion criteria

* pregnant women * patients with uncorrectable coagulopathy * diffuse extrahepatic disease * for lobar TACE and TARE - presence of bilodigestive shunt * for TARE - \>20% hepatopulmonary shunt

Design outcomes

Primary

Measure	Time frame	Description
Progression free survival	Short term (3-6 months)	Treatment Efficacy
Residual hepatic volume	within 40 days of procedure	Treatment Efficacy

Secondary

Measure	Time frame	Description
Overall survival	From date of procedure until the date of death from any cause, whichever came first, assessed up to 5 years	Overall survival

Countries

Italy

Contacts

Primary ContactFrancesco De Cobelli, MD

trialcliniciradiologia@hsr.it+39022643

Backup ContactStephanie Steidler, PhD

steidler.stephanie@hsr.it+39022643

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026